Ott, P. A., Pavlick, A. C., Johnson, D. B., Hart, L. L., Infante, J. R., Luke, J. J., … Hamid, O. (2016). A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma. In Annals of Oncology (Vol. 27, p. vi393). https://doi.org/10.1093/annonc/mdw379.42

Ott, P. A., A. C. Pavlick, D. B. Johnson, L. L. Hart, J. R. Infante, J. J. Luke, J. Lutzky, et al. “A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.” In Annals of Oncology, 27:vi393, 2016. https://doi.org/10.1093/annonc/mdw379.42.

Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, et al. A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma. In: Annals of Oncology. 2016. p. vi393.

Ott, P. A., et al. “A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.” Annals of Oncology, vol. 27, 2016, p. vi393. Scopus, doi:10.1093/annonc/mdw379.42.

Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, Lutzky J, Rothschild N, Spitler L, Cowey CL, Alizadeh A, Salama A, He Y, Bagley RG, Zhang J, Hamid O. A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma. Annals of Oncology. 2016. p. vi393.